{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:02:15Z","timestamp":1791133335641,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We pooled data from two prospective observational studies in Japan and one phase III clinical trial to assess whether delayed CINV could be controlled with a combination of three antiemetics adding a neurokinin-1 receptor antagonist and identified individual risk factors, using an inverse probability treatment-weighted analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 661 patients were evaluable in this study (median age: 64\u2009years; 391 male, and 270 female). 3 antiemetics controlled delayed nausea (33.18% vs. 42.25%; <jats:italic>p<\/jats:italic>\u2009=\u20090.0510) and vomiting (4.15% vs. 16.08%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) better than with 2 antiemetics. Female and 2 antiemetics were risk factors for both delayed nausea (female\u2014odds ratio [OR]: 1.918; 95% confidence interval [CI]: 1.292\u20132.848; <jats:italic>p<\/jats:italic>\u2009=\u20090.0012; 2 antiemetics\u2014OR: 1.485; 95% CI: 1.000\u20132.204; <jats:italic>p<\/jats:italic>\u2009=\u20090.0498) and delayed vomiting (female\u2014OR: 2.735; 95% CI: 1.410\u20135.304; <jats:italic>p<\/jats:italic>\u2009=\u20090.0029; 2 antiemetics\u2014OR: 4.551; 95% CI: 2.116\u20139.785; <jats:italic>p<\/jats:italic>\u2009=\u20090.0001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Identifying individual risk factors can facilitate personalized treatments for delayed CINV. We recommend a 3-antiemetic combination prophylaxis for CRC patients treated with L-OHP-based chemotherapy, especially for female patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08860-y","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T20:12:29Z","timestamp":1634415149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk"],"prefix":"10.1186","volume":"21","author":[{"given":"Mototsugu","family":"Shimokawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsumi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Mizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,16]]},"reference":[{"key":"8860_CR1","unstructured":"World Health Organization. Cancer Fact sheet. 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer. Accessed 2 Jun 2021."},{"issue":"12","key":"8860_CR2","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, D\u00edaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(12):2006\u201312. https:\/\/doi.org\/10.1200\/JCO.2007.14.9898.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"8860_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(1):23\u201330. https:\/\/doi.org\/10.1200\/JCO.2004.09.046.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"8860_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","volume":"25","author":"H-J Schmoll","year":"2007","unstructured":"Schmoll H-J, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(1):102\u20139. https:\/\/doi.org\/10.1200\/JCO.2006.08.1075.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"16","key":"8860_CR5","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(16):2938\u201347. https:\/\/doi.org\/10.1200\/JCO.2000.18.16.2938.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"8860_CR6","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343\u201351. https:\/\/doi.org\/10.1056\/NEJMoa032709.","journal-title":"N Engl J Med"},{"key":"8860_CR7","first-page":"85","volume":"10","author":"J Herrstedt","year":"2002","unstructured":"Herrstedt J. Nausea and emesis: still an unsolved problem in cancer patients? Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2002;10:85\u20137.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer."},{"issue":"31","key":"8860_CR8","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(31):4189\u201398. https:\/\/doi.org\/10.1200\/JCO.2010.34.4614.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"8860_CR9","first-page":"289","volume":"25","author":"F Roila","year":"2017","unstructured":"Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, et al. 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2017;25:289\u201394.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer."},{"key":"8860_CR10","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Antiemesis Version 3. 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. ."},{"key":"8860_CR11","unstructured":"Japan Society of Clinical Oncology. Guidelines for appropriate use of antiemetic drugs. Version 1. Tokyo: Kanehara; 2010."},{"key":"8860_CR12","volume-title":"JSCO guidelines for antiemetics in oncology","author":"Japan Society of Clinical Oncology","year":"2015","unstructured":"Japan Society of Clinical Oncology. JSCO guidelines for antiemetics in oncology. Tokyo: Kanehara; 2015."},{"issue":"5","key":"8860_CR13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00520-011-1180-2","volume":"20","author":"PJ Hesketh","year":"2012","unstructured":"Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2012;20(5):1043\u20137. https:\/\/doi.org\/10.1007\/s00520-011-1180-2.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer."},{"issue":"9","key":"8860_CR14","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00520-017-3679-7","volume":"25","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Shimokawa M, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J, et al. A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2017;25(9):2707\u201314. https:\/\/doi.org\/10.1007\/s00520-017-3679-7.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer."},{"issue":"3","key":"8860_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/00000421-199106000-00010","volume":"14","author":"F Roila","year":"1991","unstructured":"Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol. 1991;14(3):238\u201342. https:\/\/doi.org\/10.1097\/00000421-199106000-00010.","journal-title":"Am J Clin Oncol"},{"key":"8860_CR16","doi-asserted-by":"publisher","unstructured":"Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer. 1989;64(5):1117\u201322.\u00a0https:\/\/doi.org\/10.1002\/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R.","DOI":"10.1002\/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R"},{"issue":"11","key":"8860_CR17","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1002\/cncr.20718","volume":"101","author":"JA Roscoe","year":"2004","unstructured":"Roscoe JA, Bushunow P, Morrow GR, Hickok JT, Kuebler PJ, Jacobs A, et al. Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer. 2004;101(11):2701\u20138. https:\/\/doi.org\/10.1002\/cncr.20718.","journal-title":"Cancer."},{"issue":"6","key":"8860_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 2013;104(6):711\u20137. https:\/\/doi.org\/10.1111\/cas.12146.","journal-title":"Cancer Sci"},{"key":"8860_CR19","first-page":"450","volume":"28","author":"A du Bois","year":"1992","unstructured":"du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer Oxf Engl 1990. 1992;28:450\u20137.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"1","key":"8860_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","volume":"15","author":"D Osoba","year":"1997","unstructured":"Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of life and symptom control committees of the National Cancer Institute of Canada clinical trials group. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(1):116\u201323. https:\/\/doi.org\/10.1200\/JCO.1997.15.1.116.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"8860_CR21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","volume":"47","author":"A Molassiotis","year":"2014","unstructured":"Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage. 2014;47:839\u2013848.e4.","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"8860_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV study Group of Japan. Int J Clin Oncol. 2015;20(5):855\u201365. https:\/\/doi.org\/10.1007\/s10147-015-0786-7.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"8860_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00417474","volume":"2","author":"J Pater","year":"1994","unstructured":"Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 1994;2(3):161\u20136. https:\/\/doi.org\/10.1007\/BF00417474.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer."},{"issue":"1","key":"8860_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-017-3857-7","volume":"26","author":"K Jordan","year":"2018","unstructured":"Jordan K, Bl\u00e4ttermann L, Hinke A, M\u00fcller-Tidow C, Jahn F. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2018;26(1):21\u201332. https:\/\/doi.org\/10.1007\/s00520-017-3857-7.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer."},{"issue":"8","key":"8860_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14656566.2017.1317746","volume":"18","author":"Y Tsuji","year":"2017","unstructured":"Tsuji Y, Baba H, Takeda K, Kobayashi M, Oki E, Gotoh M, et al. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. Expert Opin Pharmacother. 2017;18(8):753\u20138. https:\/\/doi.org\/10.1080\/14656566.2017.1317746.","journal-title":"Expert Opin Pharmacother"},{"key":"8860_CR26","doi-asserted-by":"publisher","unstructured":"Matsui R, Suzuki K, Takiguchi T, Nishio M, Koike T, Hayashi T, et al. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: A multicenter, prospective, observational study. BMC Pharmacol Toxicol. 2020;21:72. https:\/\/doi.org\/10.1186\/s40360-020-00445-y.","DOI":"10.1186\/s40360-020-00445-y"},{"key":"8860_CR27","first-page":"1274","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, et al. Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer Oxf Engl 1990. 2015;51:1274\u201382.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"8860_CR28","unstructured":"ABIM. Choosing Wisely: Ten Things Physicians and Patients Should Question. https:\/\/www.asrm.org\/resources\/choosing-wisely-ten-things-physicians-and-patients-should-question\/. Accessed 2 Jun 2021."},{"issue":"5","key":"8860_CR29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.7150\/jca.13637","volume":"7","author":"H Iihara","year":"2016","unstructured":"Iihara H, Ishihara M, Fujii H, Yoshimi C, Yamada M, Suzuki A, et al. Comparison of the control of nausea and vomiting among several moderately emetic-risk chemotherapy regimens. J Cancer. 2016;7(5):569\u201375. https:\/\/doi.org\/10.7150\/jca.13637.","journal-title":"J Cancer"},{"issue":"1","key":"8860_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00520-016-3324-x","volume":"25","author":"A Molassiotis","year":"2017","unstructured":"Molassiotis A, Aapro M, Herrstedt J, Gralla R, Roila F. MASCC\/ESMO antiemetic guidelines: introduction to the 2016 guideline update. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2017;25(1):267\u20139. https:\/\/doi.org\/10.1007\/s00520-016-3324-x.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"1","key":"8860_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10147-016-1022-9","volume":"22","author":"H Takemoto","year":"2017","unstructured":"Takemoto H, Nishimura J, Komori T, Kim HM, Ota H, Suzuki R, et al. Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol. 2017;22(1):88\u201395. https:\/\/doi.org\/10.1007\/s10147-016-1022-9.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"8860_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/cas.14757","volume":"112","author":"T Hayashi","year":"2021","unstructured":"Hayashi T, Shimokawa M, Matsuo K, Nishimura J, Iihara H, Nakano T, et al. 5HT 3 RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer. Cancer Sci. 2021;112(2):744\u201350. https:\/\/doi.org\/10.1111\/cas.14757.","journal-title":"Cancer Sci"},{"issue":"4","key":"8860_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.5250","volume":"4","author":"D-S Wang","year":"2021","unstructured":"Wang D-S, Hu M-T, Wang Z-Q, Ren C, Qiu M-Z, Luo H-Y, et al. Effect of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial. JAMA Netw Open. 2021;4(4):e215250. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.5250.","journal-title":"JAMA Netw Open"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08860-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08860-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08860-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T20:14:46Z","timestamp":1634415286000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08860-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8860"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08860-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,16]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Independent Ethics Committee of National Hospital Organization Kyushu Cancer Center and conducted according to Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research involving Human Subjects. Informed consent was waived from individual patients according to the Independent Ethics Committee of National Hospital Organization Kyushu Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Satoh has received grants and honoraria from Bristol-Myers, Chugai Pharmaceutical, Elli-Lilly, Merck, Merck serono, ONO Pharmaceutical, Sanofi-Aventis, Taiho Pharmaceutical and Yakult Honsha, and received grants from Daiichi-Sankyo, Dainihon Sumitomo pharmaceutical and Gilead. He has received honoraria from Bayer, and received personal fees from Takara-Bio. Dr. Tsuji has received honoraria from Merck Serono, Eli Lilly Japan, Chugai, Taiho, Ono, Daiichi Sankyo, Yakult Honsha, Eisai and Medicon. Dr. Kogawa has received grants from Eli Lilly Japan, and Daiichi-Sankyo. Dr. Shimokawa, Dr. Hayashi, Dr. Nishimura, Dr. Fukunaga, Dr. Matsui and Dr. Mizuki have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1111"}}